Free tool
FAERS Monitor: Soolantra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206255 or its brand name (Soolantra, Ivermectin). Reports on generic versions are filed under their own applications.
Reports
4,016
Serious
2,204
55% of reports
Hospitalization
1,080
Death reported
337
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective465
- off label use420
- product use in unapproved indication290
- erythema224
- headache201
- pruritus184
- rash163
- rosacea161
- fatigue154
- nausea140
- condition aggravated139
- diarrhoea128
- asthenia127
- pyrexia125
- skin burning sensation119
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 6 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 12 |
| 2010 | 3 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 31 |
| 2014 | 46 |
| 2015 | 186 |
| 2016 | 186 |
| 2017 | 163 |
| 2018 | 185 |
| 2019 | 244 |
| 2020 | 281 |
| 2021 | 506 |
| 2022 | 403 |
| 2023 | 347 |
| 2024 | 358 |
| 2025 | 578 |
| 2026 | 451 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rosaceaSignal | 161 | 187.4 | 160.6 | 28,648 |
| skin burning sensationSignal | 119 | 8.7 | 7.3 | 806 |
| product use in unapproved indicationSignal | 290 | 6.1 | 5.5 | 1,254 |
| erythemaSignal | 224 | 5.7 | 5.0 | 874 |
| off label useSignal | 420 | 2.5 | 2.3 | 397 |
| pruritusSignal | 184 | 2.5 | 2.2 | 168 |
| condition aggravatedSignal | 139 | 2.4 | 2.0 | 113 |
| rash | 163 | 2.0 | 1.7 | 77 |
| pyrexia | 125 | 1.9 | 1.6 | 53 |
| drug ineffective | 465 | 1.8 | 1.7 | 192 |
| asthenia | 127 | 1.8 | 1.5 | 42 |
| headache | 201 | 1.7 | 1.5 | 56 |
| diarrhoea | 128 | 1.0 | 0.9 | 0 |
| fatigue | 154 | 1.0 | 0.9 | 0 |
| nausea | 140 | 0.9 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.